Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-25 @ 5:03 AM
NCT ID:
NCT05231018
Eligibility Criteria:
Inclusion Criteria:
1. Age 18-80
2. A positive COVID-19 test at the moment of enrolment for subjects in the 'patients' group
3. Adequate sensory and motor abilities, without impairments in vision, hearing and handling devices
4. Access to Internet wireless technologies.
5. A good level of Italian in terms of speaking, reading and writing.
Exclusion Criteria:
1. Present of past medical history of schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, current substance abuse, all according to the diagnostic and statistical manual fifth edition (DSM-5) (American Psychiatric Association, 2013).
2. With a diagnosis of cognitive impairment and/or dementia (e.g., mild cognitive impairment, Alzheimer's disease, Parkinson's disease);
3. Intellectual disability defined by a total IQ \< 70 in Test di Intelligenza Breve (TIB) (Sartori et al., 1997) or Standard Progressive Raven Matrices (John \& Raven, 2003)
4. Severe present medical conditions that could interfere with participation.
5. Present or past suicidal ideation or commitment.
6. Significant impairment in the use of digital and technological devices, in questionnaires and test completions, comprehension or with lack of a compliant behavior in the earliest evaluations.
7. Being enrolled in other clinical trials assessing any psychological, or experimental pharmacological treatment.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT05231018
Study Brief:
Protocol Section:
NCT05231018